Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 Years

Background. Under the name of uncommon bladder cancers are gathered rare histological entities which represent less than 5% of bladder tumors. There is not a clear and consensual therapeutic management for these entities. Purpose. To review a single-institution 10-year experience with rare form of b...

Full description

Saved in:
Bibliographic Details
Main Authors: Youssef Kadouri, Salim Lachkar, Hamza Dergamoun, Hachem El Sayegh, Lounis Benslimane, Yassine Nouini
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Advances in Urology
Online Access:http://dx.doi.org/10.1155/2020/7563703
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832567428819714048
author Youssef Kadouri
Salim Lachkar
Hamza Dergamoun
Hachem El Sayegh
Lounis Benslimane
Yassine Nouini
author_facet Youssef Kadouri
Salim Lachkar
Hamza Dergamoun
Hachem El Sayegh
Lounis Benslimane
Yassine Nouini
author_sort Youssef Kadouri
collection DOAJ
description Background. Under the name of uncommon bladder cancers are gathered rare histological entities which represent less than 5% of bladder tumors. There is not a clear and consensual therapeutic management for these entities. Purpose. To review a single-institution 10-year experience with rare form of bladder cancers detailing the diagnosis, treatment, and patient outcome. Materials and Methods. We performed a retrospective review of 27 medical records of rare bladder cancer form treated at our center between February 2006 and February 2015. The clinicopathologic features are reported with emphasis on treatment and survival. Results. Mean patient age was 65.5 ± 20 yr and 70% of patients were males. Smoking background was found in 16 cases, chronic bladder irritation factors were found in 12 cases, and past urinary tract infection was found in 11 cases. The main symptom was total hematuria (93%) causing an anemia in 16 cases. The two mean histological forms were epidermoid carcinoma (37%) and adenocarcinoma (22%). 26% of patients were found to have extended invasive tumors (T4) at diagnosis. Metastatic disease was confirmed in 8 cases. Our patients were managed by a wide range of therapeutic modalities as total cystectomy with bilateral lymph node dissection (63%), palliative chemotherapy (30%), or concomitant radiochemotherapy (7%). 55.6% of patients were alive one year after diagnosis. Epidermoid carcinoma has the best prognosis followed by leiomyosarcoma and sarcomatoid carcinoma. Neuroendocrine carcinoma has the worst outcome. The overall 5-year survival rate is 33.3%. Conclusion. The rarity and small size of these tumors justify the absence of clear and consensual therapeutic management. No role of total cystectomy concerning the conclusions could be drawn but elements suggest this may be the treatment of choice. The highly aggressive nature of those lesions justifies an aggressive and fast therapy when feasible which gives the best outcomes.
format Article
id doaj-art-1e02a5133a234bd19d2397bc185e4849
institution Kabale University
issn 1687-6369
1687-6377
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Advances in Urology
spelling doaj-art-1e02a5133a234bd19d2397bc185e48492025-02-03T01:01:25ZengWileyAdvances in Urology1687-63691687-63772020-01-01202010.1155/2020/75637037563703Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 YearsYoussef Kadouri0Salim Lachkar1Hamza Dergamoun2Hachem El Sayegh3Lounis Benslimane4Yassine Nouini5Mohammed V University, Faculty of Medicine and Pharmacy of Rabat, Ibn Sina Hospital, Department of Urology A, Rabat, MoroccoMohammed V University, Faculty of Medicine and Pharmacy of Rabat, Ibn Sina Hospital, Department of Urology A, Rabat, MoroccoMohammed V University, Faculty of Medicine and Pharmacy of Rabat, Ibn Sina Hospital, Department of Urology A, Rabat, MoroccoMohammed V University, Faculty of Medicine and Pharmacy of Rabat, Ibn Sina Hospital, Department of Urology A, Rabat, MoroccoMohammed V University, Faculty of Medicine and Pharmacy of Rabat, Ibn Sina Hospital, Department of Urology A, Rabat, MoroccoMohammed V University, Faculty of Medicine and Pharmacy of Rabat, Ibn Sina Hospital, Department of Urology A, Rabat, MoroccoBackground. Under the name of uncommon bladder cancers are gathered rare histological entities which represent less than 5% of bladder tumors. There is not a clear and consensual therapeutic management for these entities. Purpose. To review a single-institution 10-year experience with rare form of bladder cancers detailing the diagnosis, treatment, and patient outcome. Materials and Methods. We performed a retrospective review of 27 medical records of rare bladder cancer form treated at our center between February 2006 and February 2015. The clinicopathologic features are reported with emphasis on treatment and survival. Results. Mean patient age was 65.5 ± 20 yr and 70% of patients were males. Smoking background was found in 16 cases, chronic bladder irritation factors were found in 12 cases, and past urinary tract infection was found in 11 cases. The main symptom was total hematuria (93%) causing an anemia in 16 cases. The two mean histological forms were epidermoid carcinoma (37%) and adenocarcinoma (22%). 26% of patients were found to have extended invasive tumors (T4) at diagnosis. Metastatic disease was confirmed in 8 cases. Our patients were managed by a wide range of therapeutic modalities as total cystectomy with bilateral lymph node dissection (63%), palliative chemotherapy (30%), or concomitant radiochemotherapy (7%). 55.6% of patients were alive one year after diagnosis. Epidermoid carcinoma has the best prognosis followed by leiomyosarcoma and sarcomatoid carcinoma. Neuroendocrine carcinoma has the worst outcome. The overall 5-year survival rate is 33.3%. Conclusion. The rarity and small size of these tumors justify the absence of clear and consensual therapeutic management. No role of total cystectomy concerning the conclusions could be drawn but elements suggest this may be the treatment of choice. The highly aggressive nature of those lesions justifies an aggressive and fast therapy when feasible which gives the best outcomes.http://dx.doi.org/10.1155/2020/7563703
spellingShingle Youssef Kadouri
Salim Lachkar
Hamza Dergamoun
Hachem El Sayegh
Lounis Benslimane
Yassine Nouini
Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 Years
Advances in Urology
title Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 Years
title_full Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 Years
title_fullStr Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 Years
title_full_unstemmed Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 Years
title_short Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 Years
title_sort management of the uncommon bladder cancers a single center experience over 10 years
url http://dx.doi.org/10.1155/2020/7563703
work_keys_str_mv AT youssefkadouri managementoftheuncommonbladdercancersasinglecenterexperienceover10years
AT salimlachkar managementoftheuncommonbladdercancersasinglecenterexperienceover10years
AT hamzadergamoun managementoftheuncommonbladdercancersasinglecenterexperienceover10years
AT hachemelsayegh managementoftheuncommonbladdercancersasinglecenterexperienceover10years
AT lounisbenslimane managementoftheuncommonbladdercancersasinglecenterexperienceover10years
AT yassinenouini managementoftheuncommonbladdercancersasinglecenterexperienceover10years